Madrigal Pharmaceuticals, Inc. (MDGL)

Market Cap	12.04B +61.7%
Revenue (ttm)	958.40M +432.1%
Net Income	-288.28M
EPS	-12.85
Shares Out	22.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	302,739
Open	532.10
Previous Close	525.67
Day's Range	518.80 - 539.17
52-Week Range	265.00 - 615.00
Beta	-1.01
Analysts	Strong Buy
Price Target	674.45 (+28.47%)
Earnings Date	Apr 30, 2026

About MDGL

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 915
• Stock Exchange: NASDAQ
• Ticker Symbol: MDGL
• Website: https://www.madrigalpharma.com

Financial Performance

In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.

Analyst Summary

According to 12 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price target is $674.45, which is an increase of 28.47% from the latest price.

Price Target

$674.45

(28.47% upside)

Analyst Consensus: Strong Buy